Rivaroxaban for Venous Thromboembolism Prophylaxis in Abdominoplasty: A Multicenter Experience

Area of Science:

• Plastic Surgery
• Thrombosis Prevention
• Pharmacology

Background:

• Abdominoplasty is associated with a higher risk of venous thromboembolism (VTE).
• Current practices for VTE chemoprophylaxis after abdominoplasty are debated.
• This study investigates the use of rivaroxaban for VTE prevention in these patients.

Purpose of the Study:

• To evaluate the safety and efficacy of rivaroxaban for VTE prophylaxis in patients undergoing abdominoplasty.
• To assess the incidence of hematologic complications, including VTE and hematoma, in this patient cohort.

Main Methods:

• A retrospective case series included 132 abdominoplasty patients receiving rivaroxaban.
• Patients received a prophylactic dose of 10 mg daily for 7 days, starting 12 hours postoperatively.
• Outcomes measured included VTE, hematoma requiring surgery, and blood transfusion needs.

Main Results:

• Only one patient experienced a symptomatic VTE event.
• Three patients required operative evacuation of a hematoma, with successful healing.
• Two patients received blood transfusions for anemia during treatment.

Conclusions:

• Oral rivaroxaban is a safe option for VTE chemoprophylaxis in abdominoplasty patients.
• The medication demonstrated low rates of symptomatic VTE and hematoma formation.
• Routine use of rivaroxaban is continued for high-risk patients.